B Standaert, TH Pham, O Topachevskyi, MJ Postma. A One-Year Static Cross-Sectional Population Model to Assess the Infection Burden Across the Ageing Population: An Application to the Flemish County. Value in Health, Vol. 25, Issue 12, Supplement, S207, Published in issue: December 2022.
Whittington M., Topachevskyi O., Volovyk A. Moving from static to dynamic economic assessments: The process of migrating economic models built in Microsoft Excel to a User-Friendly Web Environment. Value in Health, Volume 25, Issue 7, Supplement, July 2022, Page S519
T Kärpänen, I Siddall, A Khodakivska, O Topachevskyi, M Palka-SantiniHealth Economic Model for Estimating the Cost Impact of Optimized Peripheral Intravascular Catheter Insertion and Post-Insertion Catheter Care. Value in Health, Vol. 25, Issue 12, Supplement S100–S101, Published in issue: December 2022
Open-Source Technology Stack for Creating Registries Seeding Interoperable Data Via Rest and Graphql API, O Topachevskyi, O Piniazhko, V Zverov, A, Volovyk, Y Honchar, Value in Health 25 (1), 2021, S251
Health Economic Model for Estimating the Direct Cost Impact of Adopting an Antimicrobial Vascular Access Site Dressing in Patients Receiving Haemodialysis Via Tunnelled Central Venous Catheter in the UK, I Siddall, T Karpanen, O Topachevskyi, M Palka-Santini, Value in Health 25 (1), 2021, S102
Actualization of the Budget Impact Scale for HTA Guideline in Ukraine V Serediuk, O Piniazhko, O Topachevskyi, A Masheiko, O Oleshchuk Value in Health 25 (1), 2021, S65
Potential Budget Impact of Negative Pressure Wound Therapy with Instillation and Dwell Versus Control Therapy Across Multiple Geographies, J Hargreaves, S Lookess, C Bongards, V Siabro, O Topachevskyi, Value in Health 25 (1), 2021, S78-S79
External Reference Pricing In Ukraine: The Beginning Of Price Regulation Of The Essential Medicines Procured By Hospitals, O Topachevskyi, O Piniazhko, V Serediuk, Value In Health 23, 2020, S296
Schey C, Postma MJ, Krabbe PFM, Topachevskyi O, Volovyk A, Connolly M. Assessing the Preferences for Criteria in Multi-Criteria Decision Analysis in Treatments for Rare Diseases. Front Public Health. 2020 May 8;8:162. doi: 10.3389/fpubh.2020.00162. PMID: 32457865; PMCID: PMC7225315.
Estimation of Quality-Adjusted Life YEARS (QALY) Losses Associated with COVID-19 Deaths in Ukraine, V Serediuk, O Piniazhko, O Topachevskyi, T Dumenko, L Kovtun, Value in Health 23, 2020, S562
Oncology Diseases Prioritisation LIST for Informing Priority Setting and Development of National Cancer Control PLAN in Ukraine, O Piniazhko, V Serediuk, O Topachevskyi, A Semyvolos, Value in Health 23, 2020, S460
Development of Updated Recommendations for Budget IMPACT Scale for HTA in Ukraine, O Piniazhko, A Masheiko, O Oleshchuk, V Serediuk, M Leleka, O Topachevskyi, L Kovtun, Value in Health 23, 2020, S665
Recommendations For Development Of The Scale Of Budget Impact Rate In The Evaluation Of Medicines Procurement In Ukraine, O Oleshchuk, O Piniazhko, I Romanenko, O Topachevskyi, M Leleka, Et Al, Value In Health 23, 2020, S310,
Pns221 Analysis Of Hta Dossiers Submission And Recommendation Reports For Drug Procurement And Reimbursment In Ukraine, O Oleshchuk, O Piniazhko, I Romanenko, M Klymenko, O Topachevskyi, Value In Health 22, 2020,s798
Alternative Economic Assessment for Expressing Healthcare Value and Informing Resource Allocation Decisions, M Connolly, B Standaert, N Kotsopoulos, O Topachevskyi, ISPOR Europe 2019,
Budget Impact Analysis Of The Implementation Of A Presurgical Warming Protocol To Effectively Manage Surgical Patient Normothermia, M Schmerler, O Topachevskyi, V Siabro, M Palka-santini, Value In Health 22, 2019, S650-s651
Disease Prioritisation Mcda Model For Informing Healthcare Priorities Setting In Ukraine, O Topachevskyi, O Piniazhko, I Romanenko, M Dudlei, O Oleshchuk, Et Al., Value In Health 22, 2019, S256-s257
Development Of Extended Pharmacy Reimbursement Program In Ukraine: Evidence From The Analysis Of Central Procurement Programs, O Piniazhko, O Topachevskyi, O Stefanyshyna, I Palamarchuk, F Zhao, Value In Health 22, 2019, S259
Topachevskyi O, Pinzyazhko O, Oleschuk O, Lebega O. Estimation of the supply side cost-effectiveness threshold in Ukraine. Value in Health, ISPOR 2018, Baltimore, poster presentation
Palka-Santini M, Topachevskyi O, Health economic model for estimating the direct cost impact of adopting a vascular access antimicrobial bundle of solutions in ICU settings in Germany, Value in Health, ISPOR 2018, Baltimore, poster presentation
Schey C, Connolly M, Volovyk A, Topachevskyi O, Kostopoulos N, Assessing multi-criteria decision analysis (MCDA) weights using an interactive data capture tool, Value in Health, ISPOR 2018, Baltimore, poster presentation
Zhang XH, Nievera MC, Carlos J, Lucero M, Bibera G, Atienza MI, Topachevskyi O, Navarro-Locsin CG. Cost-Effectiveness Analysis of Pneumococcal Vaccination with the Pneumococcal Polysaccharide NTHi Protein D Conjugate Vaccine in the Philippines, Value Health Reg Issues. 2014 May;3:156-166. doi: 10.1016/j.vhri.2014.04.004. Epub 2014 May 21.
Topachevskyi O., Volovyk A., Migration of health economics models to web and mobile environments. Why should models go web. Value in Health, ISPOR 2014, Amsterdam, Netherlands, poster presentation
Topachevskyi O., Standaert B, Can A multi-criteria decision (MCD) optimisation model HELP decision makers in the optimal selection of vaccines when expanding their universal mass vaccination programme? The case of Poland. ISPOR 2014, Dublin, Ireland, poster presentation
Mark Connolly; Oleksandr Topachevskyi; Baudouin Standaert, M.D. M.Sc.;Omayra Ortega, Ph.D.;Maarten Postma, Ph.D. The impact of rotavirus vaccination on discounted net tax revenue in Egypt: A government perspective analysis”. Pharmacoeconomics. 2012 Aug 1;30(8):681-95. doi: 10.2165/11597750-000000000-00000
Bakir M, Turel O, Topachevskyi O. Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey. BMC Health Serv Res. 2012 Nov 9;12:386. doi: 10.1186/1472-6963-12-386.
Topachevskyi. O, Delgleize E.,Clinical and economic burden of community acquired pneumonia in 7 countries. A comparison with invasive pneumococcal disease: ISPOR EU 2012
Ethgen O. Connolly M., Topachevskyi O. Optimizing public health decision over time: a dynamic budget optimization model with multiple criteria decision making. SPOR EU 2012
Nurgozhin T., Prof. Yermekbaeva B., Topachevskyi O. The potential public health benefit of pneumococcal conjugate vaccines in Kazakhstan. ISPOR EU 2012
Dolezal T, Skoupá J, Mrkvan T, Topachevskyi O. The potential public health benefit of pneumococcal conjugate vaccines: Example of the Czech Republic. ISPOR 13th Annual European Congress. Value Health, 2010 Nov;13(7):A436
Chang CJ, Wang PC, Huang YC, Wu BS, Wu CL, Topachevskyi O, Jung W. Cost-Effectiveness analysis of pneumococcal vaccines in Taiwan. ISPOR 13th Annual European Congress. Value Health, 2010 Nov;13(7):A438
Bakir M, Topachevskyi O, Knerer G. The potential public health benefit of the new 10-valent Pneumococcal non-typeable Haemophilus Influenza Protein-D Conjugate Vaccine (PHiD-CV). Example from Turkey. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; Nice, France, 4–8 May, 2010